AI assistant
Sending…
ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2015
Mar 10, 2015
31071_dirs_2015-03-10_2f31a9cf-63d3-4262-8622-c5460c286848.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: ARROWHEAD RESEARCH CORP (ARWR)
CIK: 0000879407
Period of Report: 2015-03-06
Reporting Person: Leone Peter Brian (VP, Strategy & Program Mgmt)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option | $7.75 | 2025-03-06 | Common Stock (85000) | Direct | |
| Stock Option | $14.54 | 2024-02-06 | Common Stock (45000) | Direct | |
| Stock Option | $4.75 | 2023-09-21 | Common Stock (10000) | Direct | |
| Stock Option | $2.79 | 2023-07-20 | Common Stock (30000) | Direct |
Footnotes
F1: Option vests and becomes exercisable over a four year period from date of grant.
More from ARROWHEAD PHARMACEUTICALS, INC.
Regulatory Filings
2026
May 7
Interim / Quarterly Report
2026
May 7
Report Publication Announcement
2026
May 7
Major Shareholding Notification
2026
May 6
Major Shareholding Notification
2026
Apr 29
Major Shareholding Notification
2026
Apr 28
Major Shareholding Notification
2026
Apr 24
Major Shareholding Notification
2026
Mar 26
Regulatory Filings
2026
Mar 20
Interim / Quarterly Report
2026
Feb 5